DRC Medicine Ltd., a healthcare and biotechnology company based in Tokyo, Japan, has announced a business combination agreement with Ribbon Acquisition Corp., a special purpose acquisition company. The agreement involves a series of transactions, including the acquisition of DRC Medicine's shares by an intermediate holding company in Japan, followed by a share exchange that will make DRC Medicine a wholly-owned subsidiary of this holding company. Subsequently, Ribbon will merge with DRC Merger Inc., a subsidiary of DRC Medicine, resulting in DRC Medicine becoming a publicly-traded company. The transaction values DRC at a pre-money equity value of $350 million and is expected to provide access to approximately $50 million in cash from Ribbon's IPO proceeds, pending certain conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.